PATA is proud to be a part of the GAP-f network , which is hosted within the Research for Health Department in the Science Division of the World Health Organization. GAP-f was established to respond to the paediatric treatment gap and to build on the model developed within the HIV community, in order to provide a sustainable mechanism for developing and making available safer, more effective, and more durable paediatric formulations against an accelerated timeline. At GAP-f, children are the top priority the network is united in a commitment to work towards ensuring that all children have access to the medicines and treatments they need to thrive. Ensuring equitable access to paediatric formulations remains a major challenge for healthcare providers on the frontlines. This is where GAP-f comes in – as a critical advocate for a sustainable and uninterrupted supply of paediatric ARV formulations, especially for low volume alternative, second- and third-line treatments. It is important to address both the supply and demand-side issues to overcome the challenges that limit access to these life-saving medications for children. PATA recently presented at the Gap-f civil society dialogue meeting on January 17th, highlighting the crucial factors involved in the rollout of new paediatric formulations. Our presentation focused on the essential role of frontline healthcare providers and community partners in accelerating the rollout process. We believe that collaboration between healthcare providers, community partners, and advocacy groups is key to achieving our goal of ensuring that all children have access to the critical ARVs they need to survive and thrive. Global Accelerator for Paediatric Formulations Network (GAP-f) Ro le of communities in accelerating roll out of new paediatric formulations
